Thomas B. Freeman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas B. Freeman has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
P R Sanberg
4 shared publicationsC W Olanow
2 shared publicationsD W Cahill
2 shared publications- Francesca Cicchetti
Centre de Recherche du CHU de Québec (CHUQ), Axe Neurosciences, Québec, QC, Canada
2 shared publications J H Kordower
Research Center for Brain Repair and Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA
2 shared publicationsA Anton
1 shared publication
Latest Publications
- 16 September 2010
- Published by Elsevier in Experimental Neurology
- Vol. 227 (1) , 1-9
Technical factors that influence neural transplant safety in Huntington's disease
- 16 September 2010
- Published by Elsevier in Experimental Neurology
- Vol. 227 (1) , 1-9
Technical factors that influence neural transplant safety in Huntington's disease
- 15 September 2009
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (37) , E105
Disease-like degeneration in neural transplants
- 15 September 2009
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (37) , E105
Disease-like degeneration in neural transplants
- Open Access
- 28 July 2009
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (30) , 12483-12488
Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration
The clinical evaluation of neural transplantation as a potential treatment for Huntington's disease (HD) was initiated in an attempt to replace lost neurons and improve patient outcomes. Two of 3 patients with HD reported here, who underwent neural transplantation containing striatal anlagen in the striatum a decade earlier, have demonstrated marginal and transient clinical benefits. Their brains were evaluated immunohistochemically and with electron microscopy for markers of projection neurons and interneurons, inflammatory cells, abnormal huntingtin protein, and host-derived connectivity. Surviving grafts were identified bilaterally in 2 of the subjects and displayed classic striatal projection neurons and interneurons. Genetic markers of HD were not expressed within the graft. Here we report in patients with HD that (i) graft survival is attenuated long-term; (ii) grafts undergo disease-like neuronal degeneration with a preferential loss of projection neurons in comparison to interneurons; (iii) immunologically unrelated cells degenerate more rapidly than the patient's neurons, particularly the projection neuron subtype; (iv) graft survival is attenuated in the caudate in comparison to the putamen in HD; (v) glutamatergic cortical neurons project to transplanted striatal neurons; and (vi) microglial inflammatory changes in the grafts specifically target the neuronal components of the grafts. These results, when combined, raise uncertainty about this potential therapeutic approach for the treatment of HD. However, these observations provide new opportunities to investigate the underlying mechanisms involved in HD, as well as to explore additional therapeutic paradigms.
- 28 July 2009
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (30) , 12483-12488
Open AccessNeural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration
The clinical evaluation of neural transplantation as a potential treatment for Huntington's disease (HD) was initiated in an attempt to replace lost neurons and improve patient outcomes. Two of 3 patients with HD reported here, who underwent neural transplantation containing striatal anlagen in the striatum a decade earlier, have demonstrated marginal and transient clinical benefits. Their brains were evaluated immunohistochemically and with electron microscopy for markers of projection neurons and interneurons, inflammatory cells, abnormal huntingtin protein, and host-derived connectivity. Surviving grafts were identified bilaterally in 2 of the subjects and displayed classic striatal projection neurons and interneurons. Genetic markers of HD were not expressed within the graft. Here we report in patients with HD that (i) graft survival is attenuated long-term; (ii) grafts undergo disease-like neuronal degeneration with a preferential loss of projection neurons in comparison to interneurons; (iii) immunologically unrelated cells degenerate more rapidly than the patient's neurons, particularly the projection neuron subtype; (iv) graft survival is attenuated in the caudate in comparison to the putamen in HD; (v) glutamatergic cortical neurons project to transplanted striatal neurons; and (vi) microglial inflammatory changes in the grafts specifically target the neuronal components of the grafts. These results, when combined, raise uncertainty about this potential therapeutic approach for the treatment of HD. However, these observations provide new opportunities to investigate the underlying mechanisms involved in HD, as well as to explore additional therapeutic paradigms.
- 11 July 2008
- Published by Elsevier in Neurobiology of Disease
- Vol. 32 (2) , 229-242
The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors
- 11 July 2008
- Published by Elsevier in Neurobiology of Disease
- Vol. 32 (2) , 229-242
The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors
- 1 January 2001
- Vol. 86, 435-45
Neural transplantation in Parkinson's disease.
In conclusion, proof of the principle exists that neural grafts can survive transplantation in PD and that this graft survival is related to preliminary evidence of clinical benefit and improvement on FD-PET. Two prospective, randomized, surgical placebo-controlled trials of fetal tissue transplantation for the treatment of PD will be published in the near future, as will results of a placebo-controlled xenograft trial. Lifelong survival of human fetal nigral grafts is likely. The striatum is comparatively simple to target surgically in comparison to other sites such as the subthalamic nucleus. Several new sources of dopamine cells are being developed for transplantation purposes. Long-term monitoring for toxicity, such as the development of dyskinesias, will be needed, and dose-escalation trials should be performed slowly due to the irreversible nature of transplants. There are numerous ways to improve current techniques of neural transplantation.
- 1 January 2001
- Vol. 86, 435-45
Neural transplantation in Parkinson's disease.
In conclusion, proof of the principle exists that neural grafts can survive transplantation in PD and that this graft survival is related to preliminary evidence of clinical benefit and improvement on FD-PET. Two prospective, randomized, surgical placebo-controlled trials of fetal tissue transplantation for the treatment of PD will be published in the near future, as will results of a placebo-controlled xenograft trial. Lifelong survival of human fetal nigral grafts is likely. The striatum is comparatively simple to target surgically in comparison to other sites such as the subthalamic nucleus. Several new sources of dopamine cells are being developed for transplantation purposes. Long-term monitoring for toxicity, such as the development of dyskinesias, will be needed, and dose-escalation trials should be performed slowly due to the irreversible nature of transplants. There are numerous ways to improve current techniques of neural transplantation.
- 1 October 1994
- Vol. 81 (10) , 689-94
Recent advances in neural transplantation. Relevance to neurodegenerative disorders.
Anatomical and behavioral characterizations of neural transplants, whether within (allograft) or across (xenograft) species, have provided evidence that the transplant survives, integrates with the host tissue, and may lead to functional recovery. Several animal models of neurodegenerative disorders demonstrate the feasibility of using neural transplantation as an alternative treatment for these human diseases. While more elaborate basic animal studies are needed, clinical trials have begun. Neural transplantation is currently used as an experimental treatment for Parkinson's disease and several investigators have suggested using the same treatment procedure for other neurodegenerative disorders, such as Huntington's and Alzheimer's disease.
- 1 October 1994
- Vol. 81 (10) , 689-94
Recent advances in neural transplantation. Relevance to neurodegenerative disorders.
Anatomical and behavioral characterizations of neural transplants, whether within (allograft) or across (xenograft) species, have provided evidence that the transplant survives, integrates with the host tissue, and may lead to functional recovery. Several animal models of neurodegenerative disorders demonstrate the feasibility of using neural transplantation as an alternative treatment for these human diseases. While more elaborate basic animal studies are needed, clinical trials have begun. Neural transplantation is currently used as an experimental treatment for Parkinson's disease and several investigators have suggested using the same treatment procedure for other neurodegenerative disorders, such as Huntington's and Alzheimer's disease.